# Nicotinamide Versus Sevelamer Hydrochloride on Phosphatemia Control on Chronic Hemodialysed Patients

Study · id `cardio:ct-nct01011699` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01011699](<https://clinicaltrials.gov/study/NCT01011699>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01011699

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 176 participants.

## Technical summary

Registry record NCT01011699. Randomized; no masking; primary purpose treatment. Start 2010-01 (registry gives no type); primary completion 2013-06 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 176 participants (enrolled count; ClinicalTrials.gov record NCT01011699, source copy `cardio:ctgov-nct01011699-2016-05-16`, retrieved 2026-10-26)
- Start date: 2010-01 (registry gives no type) (ClinicalTrials.gov record NCT01011699, source copy `cardio:ctgov-nct01011699-2016-05-16`, retrieved 2026-10-26)
- Primary completion: 2013-06 (actual) (ClinicalTrials.gov record NCT01011699, source copy `cardio:ctgov-nct01011699-2016-05-16`, retrieved 2026-10-26)
- Completion: 2013-06 (actual) (ClinicalTrials.gov record NCT01011699, source copy `cardio:ctgov-nct01011699-2016-05-16`, retrieved 2026-10-26)
- Countries: France (ClinicalTrials.gov record NCT01011699, source copy `cardio:ctgov-nct01011699-2016-05-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01011699-2016-05-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: Nicotinamide Versus Sevelamer Hydrochloride on Phosphatemia Control on Chronic Hemodialysed Patients
- Acronym: NICOREN
- Condition: Chronic Renal Failure
- Condition: Hemodialysis
- Intervention (Drug): nicotinamide
- Intervention (Drug): sevelamer
- Intervention (Drug): cinacalcet
- Lead sponsor: Centre Hospitalier Universitaire, Amiens
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)

## Provenance

Content hash: 97b42bf7c1dbc93a4a0ea67594000f099ea4b4370f35456a286d9f9c8308b72d
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
